Details of the Drug

General Information of Drug (ID: DMNQXV8)

Drug Name

LGX818

Synonyms

Encorafenib; 1269440-17-6; LGX-818; Encorafenib (LGX818); UNII-8L7891MRB6; LGX 818; 8L7891MRB6; Encorafenib [USAN:INN]; LGX-818(Encorafenib)

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Approved	[1]

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

540

Topological Polar Surface Area (xlogp)

2.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2 h [2]
Clearance: The clearance of drug is 14 L/h [3]
Elimination: 47% (5% unchanged) of the administered dose was recovered in the feces and 47% (2% unchanged) was recovered in the urine [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 3.5 hours [2]
Metabolism: The drug is metabolized via the liver [2]
Vd: The volume of distribution (Vd) of drug is 164 L [3]

Chemical Identifiers

Formula: C22H27ClFN7O4S
IUPAC Name: methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate
Canonical SMILES: C[C@@H](CNC1=NC=CC(=N1)C2=CN(N=C2C3=C(C(=CC(=C3)Cl)NS(=O)(=O)C)F)C(C)C)NC(=O)OC
InChI: InChI=1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1
InChIKey: CMJCXYNUCSMDBY-ZDUSSCGKSA-N

Cross-matching ID

PubChem CID: 50922675
CAS Number: 1269440-17-6
DrugBank ID: DB11718
TTD ID: D0TK7R
INTEDE ID: DR0578
ACDINA ID: D01046

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serine/threonine-protein kinase B-raf (BRAF)	TTWCGQT	BRAF_HUMAN	Modulator	[4]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[5]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Melanoma

ICD Disease Classification

2C30

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Serine/threonine-protein kinase B-raf (BRAF)	DTT	BRAF	3.00E-01	0.1	0.2
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	9.10E-03	5.38E-02	2.83E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.75E-01	3.78E-02	1.44E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from LGX818 (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of LGX818 and Ivosidenib.	Acute myeloid leukaemia [2A60]	[35]
Arn-509	DMT81LZ	Major	Increased metabolism of LGX818 caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[36]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of LGX818 and Levalbuterol.	Asthma [CA23]	[37]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of LGX818 caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[36]
Pexidartinib	DMS2J0Z	Major	Increased metabolism of LGX818 caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[36]
LY2835219	DM93VBZ	Moderate	Increased metabolism of LGX818 caused by LY2835219 mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[36]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of LGX818 and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[36]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of LGX818 and Osilodrostat.	Cushing syndrome [5A70]	[36]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of LGX818 and Deutetrabenazine.	Dystonic disorder [8A02]	[38]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of LGX818 and Ingrezza.	Dystonic disorder [8A02]	[36]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of LGX818 caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[36]
Bay 80-6946	DMLOS5R	Moderate	Increased metabolism of LGX818 caused by Bay 80-6946 mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[36]
Ripretinib	DM958QB	Moderate	Decreased clearance of LGX818 due to the transporter inhibition by Ripretinib.	Gastrointestinal stromal tumour [2B5B]	[39]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of LGX818 and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[40]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of LGX818 and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Berotralstat	DMWA2DZ	Major	Decreased clearance of LGX818 due to the transporter inhibition by Berotralstat.	Innate/adaptive immunodeficiency [4A00]	[41]
Brigatinib	DM7W94S	Moderate	Increased metabolism of LGX818 caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[36]
PF-06463922	DMKM7EW	Major	Increased metabolism of LGX818 caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[36]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of LGX818 and Selpercatinib.	Lung cancer [2C25]	[40]
IPI-145	DMWA24P	Major	Decreased metabolism of LGX818 caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[36]
Ubrogepant	DM749I3	Moderate	Decreased clearance of LGX818 due to the transporter inhibition by Ubrogepant.	Migraine [8A80]	[42]
Rimegepant	DMHOAUG	Moderate	Decreased clearance of LGX818 due to the transporter inhibition by Rimegepant.	Migraine [8A80]	[43]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of LGX818 and Ozanimod.	Multiple sclerosis [8A40]	[44]
Fedratinib	DM4ZBK6	Major	Decreased metabolism of LGX818 caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[36]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of LGX818 and Entrectinib.	Non-small cell lung cancer [2C25]	[39]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of LGX818 and Rucaparib.	Ovarian cancer [2C73]	[36]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of LGX818 and Triclabendazole.	Parasitic worm infestation [1F90]	[36]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of LGX818 and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[45]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of LGX818 and Lefamulin.	Pneumonia [CA40]	[46]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of LGX818 and Relugolix.	Prostate cancer [2C82]	[40]
Voxelotor	DMCS6M5	Major	Decreased metabolism of LGX818 caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[36]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of LGX818 caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[36]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of LGX818 and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[47]
Elagolix	DMB2C0E	Moderate	Increased metabolism of LGX818 caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[36]
-----------


⏷ Show the Full List of 34 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Succinic acid	E00044	1110	Buffering agent
Crospovidone	E00626	Not Available	Disintegrant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Gelatin	E00630	Not Available	Other agent
Magnesium stearate	E00208	11177	lubricant
Poloxamer 188	E00645	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Haematite red	E00236	14833	Colorant
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
Copovidone	E00693	Not Available	Film/membrane-forming agent; Modified-release agent; Binding agent
--------------------


⏷ Show the Full List of 13 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Encorafenib 75 mg capsule	75 mg	Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
3	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
4	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
5	Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018 Mar;30(2):125-133.
6	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
7	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
8	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
9	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
10	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
11	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
12	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
13	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
14	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
15	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
16	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
17	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
18	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
19	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
20	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
21	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
22	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
23	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
24	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
25	Clinical pipeline report, company report or official report of GlaxoSmithKline (2011).
26	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
27	Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors. Pigment Cell Melanoma Res. 2014 Mar;27(2):253-62.
28	Clinical pipeline report, company report or official report of Ambit Biosciences.
29	BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol Cancer Ther. 2015 Oct;14(10):2187-97.
30	National Cancer Institute Drug Dictionary (drug id 688029).
31	National Cancer Institute Drug Dictionary (drug id 680347).
32	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
33	Clinical pipeline report, company report or official report of Exelixis (2011).
34	Clinical pipeline report, company report or official report of ABM Therapeutics.
35	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
36	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
37	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
38	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
39	Cerner Multum, Inc. "Australian Product Information.".
40	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
41	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
42	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
43	Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
44	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
45	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
46	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
47	Canadian Pharmacists Association.